Havana, August 30 (RHC)-- The combined anti-Covid-19 vaccination with the Chinese immunogen Sinopharm and the Cuban drug Soberana Plus will be administered in at-risk groups in the provinces of Cienfuegos and Artemisa, local press reported.
According to Ileana Morales, an executive from the Ministry of Public Health (MINSAP), last August 10, the national regulatory authority of medicines approved the mass immunization with the Chinese product in the province of Cienfuegos, which will be extended to the western province of Artemisa.
Recently, the Cuban scientist Dagmar García, expert of the Finlay Vaccine Institute (IFV) stated in her Facebook account that this institution, together with MINSAP, proposed such an implementation strategy for the province of Cienfuegos due to the complicated epidemiological scenario.
The anti-Covid-19 drug, donated to Cuba by the Beijing Biological Products Institute, is being administered to the population aged 19 and older, in two doses every 21 days, plus a last dose of the Cuban Soberana Plus, with the same time interval.
This application strategy will allow maximizing the impact of the products in a short period since the combination with Soberana Plus should increase the efficacy of the Chinese vaccine, which is good enough to intervene in the pandemic indicators, said García.
Sinopharm is an immunogen recommended by the World Health Organization. It is used in more than 85 countries to deal with the disease, and it demonstrated efficacy in clinical trials of 79 percent.
Soberana Plus represents a Cuban product authorized for emergency use to boost the immunity of previously vaccinated individuals.
Today, the scientist concluded that the world is combining and exchanging vaccines as a strategy to maximize availability and efficacy.